Xenetic Biosciences (NASDAQ:XBIO) Issues Quarterly Earnings Results

Xenetic Biosciences (NASDAQ:XBIO) announced its earnings results on Thursday. The company reported ($0.72) EPS for the quarter, FiscalAI reports. The firm had revenue of $0.73 million for the quarter. Xenetic Biosciences had a negative return on equity of 40.62% and a negative net margin of 75.90%.

Xenetic Biosciences Stock Down 11.0%

Shares of XBIO stock opened at $1.66 on Friday. The stock has a 50-day simple moving average of $2.48 and a 200 day simple moving average of $2.81. Xenetic Biosciences has a fifty-two week low of $1.58 and a fifty-two week high of $4.94.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xenetic Biosciences in a research note on Thursday, October 15th. One analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, Xenetic Biosciences has a consensus rating of “Sell”.

About Xenetic Biosciences

Xenetic Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for oncology indications. The company’s primary focus is its XCART platform, an autologous cell-therapy technology designed to modify a patient’s own T cells to recognize and attack cancer cells. Xenetic has applied the XCART platform to potential treatments for B-cell malignancies, including programs intended to target specific antigens found on cancerous B cells. The company’s research and development activities have centered on advancing personalized immunotherapies through preclinical and clinical development.